Detection of rare dividing cells in blood samples and complex cell mixtures is currently not feasible with existing techniques, which are insufficiently sensitive for biomedical applications. This is critical for applications such as quantifying proliferating cancer and T cells, determining vaccine efficacy, and measuring tumor immune responses or emerging pathogens. Existing methods struggle to detect rare dividing cells, typically less than 1 in 100,000. ProliSpot addresses this gap, with the potential for significant scientific and societal impact by advancing therapies and diagnostics.
After consulting with clinicians, we identified CAR T-cell potency testing as the primary clinical application. CAR-T therapy is an immunotherapy that uses the immune system to combat cancer, but current potency tests are inaccurate and difficult to standardize. ProliSpot offers a solution, enabling more accurate and timely CAR-T potency testing, ensuring that patients receive functional CAR-T cells, thus enhancing treatment outcomes. Initially, we are targeting the RUO cell proliferation market to generate early revenue while simultaneously pursuing CAR-T therapy applications, validating both the technology and business support.
